BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9596683)

  • 1. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.
    Cordone I; Masi S; Mauro FR; Soddu S; Morsilli O; Valentini T; Vegna ML; Guglielmi C; Mancini F; Giuliacci S; Sacchi A; Mandelli F; Foa R
    Blood; 1998 Jun; 91(11):4342-9. PubMed ID: 9596683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity.
    Cordone I; Matutes E; Catovsky D
    Leukemia; 1992 Sep; 6(9):902-6. PubMed ID: 1387694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated
    Bravo-Navas S; Yáñez L; Romón Í; Pipaón C
    FASEB J; 2019 Sep; 33(9):10477-10489. PubMed ID: 31251079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis.
    Lens D; Dyer MJ; Garcia-Marco JM; De Schouwer PJ; Hamoudi RA; Jones D; Farahat N; Matutes E; Catovsky D
    Br J Haematol; 1997 Dec; 99(4):848-57. PubMed ID: 9432033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
    Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
    Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
    Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some oncogene and tumour suppressor gene protein products expression in B-cell chronic lymphocytic leukaemia.
    Niewiadomska H; Mirowski M; Kulczycka D; Najder M; Balcerczak E; Błoński JZ
    Cytobios; 2000; 103(404):159-68. PubMed ID: 11086711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
    Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
    J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
    Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
    Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia.
    Vasconcelos Y; Davi F; Levy V; Oppezzo P; Magnac C; Michel A; Yamamoto M; Pritsch O; Merle-Béral H; Maloum K; Ajchenbaum-Cymbalista F; Dighiero G
    J Clin Oncol; 2003 Nov; 21(21):3928-32. PubMed ID: 14581416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of TP53 Mutation in B-Cell Chronic Lymphocytic Leukaemia and its Association with Lymphocyte Doubling Time.
    Ali SM; Irfan SM; Raza N
    J Coll Physicians Surg Pak; 2023 Nov; 33(11):1249-1253. PubMed ID: 37926876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.